Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Heparin Market Outlook

The global heparin market size was valued at USD 9.08 billion in 2023, driven by the growing prevalence of cardiovascular and other chronic disorders across the globe. The market is expected to grow at a CAGR of 4.41% during the forecast period of 2024-2032, with the values likely to rise from USD 9.48 billion in 2024 to USD 13.38 billion by 2032.

Global Heparin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Heparin Market Overview

Heparin is an anticoagulant used to treat and prevent the formation of blood clots. Heparin cannot be absorbed via the digestive system, so it is taken intravenously or injected below the skin. Heparin drugs work by making thrombin (a coagulation factor) inactive, preventing clot formation in the blood. Heparin is used for certain medical conditions such as venous thromboembolism (VTE), deep vein thrombosis (DVT), heart attack, or after a medical procedure like heart surgery.

The heparin market growth is driven by the increasing prevalence of cardiovascular diseases, which is poised to fuel the demand for anticoagulant products. Venous thromboembolism (VTE), characterized by the formation of a blood clot in the veins, and affects 1 in 12  individuals in the western region, with 20% of affected individuals dying within an year of diagnosis. As a result, there is a high demand for anticoagulants and is expected to increase in the forecast period. In addition, growth in healthcare expenditure and rising patient awareness are some of the key factors poised to accelerate the market growth in coming years.

Increased Approval for Heparin Drugs by Regulatory Bodies

The surge in drug approvals by health authorities such as the United States Food and Drug Administration (FDA) along with the increased use of heparin in various drug formulations is projected to increase the heparin market share in the coming years. In November 2023 , the FDA approved DefenCath, a formulation of taurolidine and heparin, developed by a United States-based biopharmaceutical company CorMedix Inc. The therapeutic product DefenCath is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections (CRBSIs) by 71%  in adult hemodialysis patients. The approval is based on the positive results from the phase 3 LOCK IT-100 trial.

Rise in Product Launches to Meet the Rising Heparin Market Demand

In June 2023 , Techdow USA Inc., a pharmaceutical company announced the launch of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a low molecular weight heparin (LMWH). Available at different strengths such as 30mg, 100mg, and 150mg, the drug prevents the formation of blood clots in various medical conditions. The U.S. FDA granted the final approval of the Abbreviated New Drug Application for the product as well. The commercial release and approval of such products indicate the commitment of the key market players to meet the rising demand for heparin.

Global Heparin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Heparin Market Segmentation

Market Breakup by Products

  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

Breakup by Source

  • Bovine
  • Porcine

Market Breakup by Applications

  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation and Heart Attack
  • Coronary Artery Disease
  • Other Applications

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Global Heparin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Heparin Market Regional Analysis

North America accounts for the largest share of the heparin market which can be attributed to the increasing prevalence of cardiovascular diseases in the region. According to the data released by the American Heart Association , cardiovascular diseases stand as the leading cause of death in the United States. Heparin, as an anticoagulant, plays a crucial role in treating and managing cardiovascular conditions and thus, has a significant demand in the region. In addition, the growth of the market is propelled by the presence of the key market players and robust support from the government.

Asia Pacific also holds a significant heparin market share and is anticipated to witness rapid growth in the coming years. The major key drivers are the rising patient awareness and disease burden. Furthermore, technological advancements and intensive research and development activities to improve the healthcare system are expected to accelerate the market growth. In May 2023 , a team of researchers at the Thailand Excellence Center for Tissue Engineering and Stem Cells, Department of Biochemistry from Chiang Mai University discovered an alternative source of heparin. They extracted acharan sulfate (heparin-like substances) from the mucus of the giant African snail, Achatina fulica, which has the potential to address the rising demand for the essential anticoagulant.

Global Heparin Market: Competitor Landscape

In November 2023 , a multinational Danish pharmaceutical company, Leo Pharma, announced a cooperation agreement with a Greek pharmaceutical company, Vianex SA. Under the terms of agreement, Vianex will be responsible for manufacturing low molecular weight heparin and unfractionated heparin. On the other hand, Leo Pharma will handle the distribution of the final product. The production of five product codes is estimated to amount to several million vials per year. The objective of the collaboration is to increase their market presence and expand the distribution of their products in over 23 countries. This indicates a market trend of increasing collaborations among the leading market players to boost their manufacturing capacity. Consequently, this will fuel the heparin market share in the forecast period.

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

  • Aspen Pharmacare Holdings Limited
  • B Braun Melsungen AG
  • Baxter International
  • Dr. Reddy's Laboratories
  • Hebei Changshan Biochemical Pharmaceutical
  • Leo Pharma AS
  • Opocrin SpA
  • Pfizer Inc
  • Techdow USA
  • Viatris Inc.
  • Novartis AG
  • Aspen Oss
  • Leo Pharma A/S
  • Hikma Pharmaceuticals PLC
  • Sanofi

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Products
  • Source
  • Applications
  • Region
Breakup by Products
  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)
Breakup by Source
  • Bovine
  • Porcine
Breakup by Applications
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation and Heart Attack
  • Coronary Artery Disease
  • Other Applications
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Aspen Pharmacare Holdings Limited
  • B Braun Melsungen AG
  • Baxter International
  • Dr. Reddy's Laboratories
  • Hebei Changshan Biochemical Pharmaceutical
  • Leo Pharma AS
  • Opocrin SpA
  • Pfizer Inc
  • Techdow USA
  • Viatris Inc.
  • Novartis AG
  • Aspen Oss
  • Leo Pharma A/S
  • Hikma Pharmaceuticals PLC
  • Sanofi

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

The market attained a value of about USD 9.08 billion in 2023 driven by the growing prevalence of cardiovascular and other chronic disorders across the globe.

The market is anticipated to grow at a CAGR of 4.41% during the forecast period of 2024-2032, likely to reach a market value of USD 13.38 billion by 2032.

The increased expenditure on healthcare and the rising patient awareness are some of the factors contributing to the market demand.

The high demand for anticoagulants and the growing use of heparin in various drug formulations are the major trends driving the heparin market. In November 2023, the FDA approved DefenCath, a formulation of taurolidine and heparin, developed by CorMedix Inc. It is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections (CRBSIs) by 71% in adult hemodialysis patients.

The various products in the market are unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH).

Based on the source, the market is segmented into bovine and porcine.

Application areas of heparin include deep vein thrombosis (DVT), atrial fibrillation & heart attack, and coronary artery disease, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key players involved in the market are Aspen Pharmacare Holdings Limited, B Braun Melsungen AG, Baxter International, Dr. Reddy's Laboratories, Hebei Changshan Biochemical Pharmaceutical, Leo Pharma AS, Opocrin SpA, Pfizer Inc, Techdow USA, Viatris Inc., Novartis AG, Aspen Oss, Leo Pharma A/S, Hikma Pharmaceuticals PLC, and Sanofi.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124